lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,238 rows where filing_year = 2019 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2260471 | PENN AVENUE PARTNERS d825b8cf-4fed-42a9-9ad0-648b0183f837 | 1T | PENN AVENUE PARTNERS | 400918672 | PURDUE PHARMA L.P. | 2019 | first_quarter | PHA | Monitoring legislative and regulatory activities impacting the pharmaceutical industry. | 20000 | 0 | 1 | 2019-01-16T17:34:48.747000-05:00 | ||
| 2260689 | ML STRATEGIES, LLC 43b73cd0-67f9-42d9-90c7-da39d34987f9 | 1T | ML STRATEGIES, LLC | 25603 | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | 2019 | first_quarter | PHA | Issues related to prescription drug pricing | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 1 | 2019-03-15T14:42:25.797000-04:00 | |
| 2260783 | NATIONAL RURAL HEALTH ASSOCATION df3ef15d-ae63-4f4e-9752-24473b91d23a | Q1 | NATIONAL RURAL HEALTH ASSOCATION | 53048 | NATIONAL RURAL HEALTH ASSOCATION | 2019 | first_quarter | PHA | The 340B Program and drug pricing | Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE | 16182 | 0 | 0 | 2019-03-27T12:59:52.753000-04:00 | |
| 2260827 | REPUBLIC CONSULTING, LLC aeb33366-a4de-4c70-9877-d780ea2a8637 | Q1 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2019 | first_quarter | PHA | Monitor Data and Science Policy. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-03-30T12:58:06.777000-04:00 | |
| 2261254 | THE KUTLER GROUP e6c9c6c9-f1f8-4870-aafc-e04f3a1ef809 | Q1 | THE KUTLER GROUP | 401103966 | PRIME THERAPEUTICS | 2019 | first_quarter | PHA | drug pricing issues | HOUSE OF REPRESENTATIVES,SENATE | 24000 | 0 | 0 | 2019-04-02T15:33:16.990000-04:00 | |
| 2261668 | PENN AVENUE PARTNERS a32dcc98-e600-4ac4-95b7-106b6175e9aa | Q1 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2019 | first_quarter | PHA | Regulatory and legislative issues impacting Alkermes. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-04T11:04:44.667000-04:00 | |
| 2261759 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION ed38ec67-d7b7-4760-be8c-ebad0321dd6e | Q1 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION | 401103437 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION | 2019 | first_quarter | PHA | Compounding | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 0 | 0 | 2019-04-04T14:11:45.137000-04:00 | ||
| 2261847 | RED+BLUE STRATEGIES 597081be-a5cb-4d15-9286-5b161fa56365 | Q1 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2019 | first_quarter | PHA | CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace. C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-04-04T15:25:32.360000-04:00 | |
| 2261870 | MCDERMOTT WILL & SCHULTE LLP 155d27a2-111e-428c-837a-1031a83f87c7 | Q1 | MCDERMOTT WILL & SCHULTE LLP | 24338 | MAXOR NATIONAL PHARMACY SERVICES, LLC | 2019 | first_quarter | PHA | Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 30000 | 0 | 0 | 2019-04-04T15:40:40.693000-04:00 | |
| 2261893 | NATIONAL RURAL HEALTH ASSOCATION 488dffff-72c2-4c09-bf6e-2d57b7ae675a | 1A | NATIONAL RURAL HEALTH ASSOCATION | 53048 | NATIONAL RURAL HEALTH ASSOCATION | 2019 | first_quarter | PHA | The 340B Program and drug pricing | Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE | 16182 | 0 | 0 | 2019-04-04T15:59:50.123000-04:00 | |
| 2261902 | RED+BLUE STRATEGIES 7c6b82f0-05e1-4d0b-8129-a172937a4967 | Q1 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2019 | first_quarter | PHA | Issues related to the modernization of OTC monograph reform. Issues related to the implementation on the SUPPORT Act (P.L. 115-271) regarding MAT treatment. Issues related to curbing antibiotic resistance. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-04T16:07:52.587000-04:00 | |
| 2262171 | MS. TAMI WAHL 78aefeed-3ffc-41d1-a17e-e88ad872e04a | 1T | MS. TAMI WAHL | 401104405 | ROCK & ASSOCIATES | 2019 | first_quarter | PHA | Legislation impacting the operation of pharmacy compounding, and access to compounded medications. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 1 | 2019-04-05T15:41:55.187000-04:00 | |
| 2262178 | MS. TAMI WAHL b3d56d01-29ca-477c-abae-0088c213da0e | 1T | MS. TAMI WAHL | 401104405 | ROCK & ASSOCIATES ON BEHALF OF PARRY, ROMANI, DECONCINI & SYMMS | 2019 | first_quarter | PHA | Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act (503B)) is in alignment with the statutory language. Legislative efforts include working on draft guidance documents issued by FDA. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE,White House Office | 0 | 1 | 2019-04-05T16:10:58.910000-04:00 | ||
| 2262434 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE c0e27650-deaf-46d5-b803-82fb10537e71 | Q1 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | 11003 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | 2019 | first_quarter | PHA | CCAGW and NTU Urge Representatives to Oppose H.R. 107 CCAGW Offers Perspective on Medicare Drug Pricing Hearing CCAGW Offers Perspective on Medicare Drug Pricing Hearing CCAGW and NTU Urge Senators to Oppose H.R. 107 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-08T11:04:33.497000-04:00 | |
| 2262470 | ACG ADVOCACY 9c68712d-07e8-4d06-a44d-b124585ccf58 | Q1 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2019 | first_quarter | PHA | Competition Policy Issues. Drug Pricing Policy Issues. Data privacy and DIR fee reform. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-04-08T12:09:56.253000-04:00 | |
| 2262756 | AMERICAN COLLEGE OF CLINICAL PHARMACY d34f67f2-7da7-455b-b142-9f4b17f1ca1e | Q1 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2019 | first_quarter | PHA | Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2019-04-09T09:12:15.970000-04:00 | |
| 2262853 | MCDERMOTT+ LLC 77fec801-6297-4042-93ce-b149cb7ab488 | Q1 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2019 | first_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-09T12:00:07.900000-04:00 | |
| 2262887 | UC HEALTH 35077f33-fe7b-4a20-b0a0-080de7851d81 | Q1 | UC HEALTH | 401103195 | UC HEALTH | 2019 | first_quarter | PHA | 340B, drug prices | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-04-09T13:02:53.750000-04:00 | ||
| 2262983 | RED+BLUE STRATEGIES 7c42866b-64ea-4ed3-8f55-3628e709489f | Q1 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2019 | first_quarter | PHA | Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-04-09T14:59:00.710000-04:00 | |
| 2262998 | RED+BLUE STRATEGIES c2765d73-375c-42be-abd5-fb8b7fb503d7 | Q1 | RED+BLUE STRATEGIES | 400693064 | CIGNA CORPORATION | 2019 | first_quarter | PHA | Issues related to Trump Administration proposals and regulations regarding drug pricing reforms, regulations regarding rebates, and related guidances focused on affordability and accessibility to prescription medications in the United States. Proposals, guidances and call letters and impacting Medicare Part D and the role of Pharmacy Benefit Managers. Issues related to transparency in the prescription drug marketplaces including new technologies to improve physician and patient access to real time pricing questions and concerns. Issues related to utilization and access to e- prescribing tools. Issues focused on the promotion of fair competition in the prescription drug market place, including policies focused on patents, biosimilars and generic medications. | SENATE | 60000 | 0 | 0 | 2019-04-09T15:17:20.657000-04:00 | |
| 2263102 | HOLLAND & KNIGHT LLP dfb26111-7424-4cd7-9132-928b9dbdab6e | Q1 | HOLLAND & KNIGHT LLP | 18466 | TEVA PHARMACEUTICALS USA, INC. | 2019 | first_quarter | PHA | Drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-09T16:16:30.183000-04:00 | |
| 2263259 | RUBICON ADVISORS, LLC 1d439711-9207-420d-9077-68ddf0bd49fc | Q1 | RUBICON ADVISORS, LLC | 315091 | DYNAVAX TECHNOLOGIES | 2019 | first_quarter | PHA | Prescription Drug User Fee | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2019-04-10T08:32:20.017000-04:00 | |
| 2263260 | RUBICON ADVISORS, LLC da57a9f4-74fd-4266-83b9-e55a580f32f8 | Q1 | RUBICON ADVISORS, LLC | 315091 | DR. REDDY'S LABORATORIES, LTD | 2019 | first_quarter | PHA | Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 45000 | 0 | 0 | 2019-04-10T08:45:21.003000-04:00 | |
| 2263262 | RUBICON ADVISORS, LLC 3bc206cc-369c-4322-adda-d751837d6da7 | Q1 | RUBICON ADVISORS, LLC | 315091 | CONSCIOUS DISCIPLINE | 2019 | first_quarter | PHA | Medicare | HOUSE OF REPRESENTATIVES,SENATE | 37500 | 0 | 0 | 2019-04-10T08:51:23.010000-04:00 | |
| 2263264 | RUBICON ADVISORS, LLC 698a4230-c4fe-4792-a588-f9abdab53985 | 1T | RUBICON ADVISORS, LLC | 315091 | LANNETT COMPANY, INC | 2019 | first_quarter | PHA | Medicare and Medicaid, Generic Prescription | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 1 | 2019-04-10T08:57:25.017000-04:00 | |
| 2263323 | OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC cec0d74a-970d-44ae-983f-dab1951fb238 | Q1 | OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC | 30212 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2019 | first_quarter | PHA | Drug pricing, Direct and Indirect remuneration fees, Medicare | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-10T10:01:13.990000-04:00 | |
| 2263356 | NOVO NORDISK INC. 3efbb531-3d8c-45d3-8d75-1f6bd87ff22a | Q1 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2019 | first_quarter | PHA | H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 440000 | 0 | 0 | 2019-04-10T10:36:37.830000-04:00 | |
| 2263593 | LINCOLN PARK GROUP L.L.C. a5cce892-4114-406e-9dde-1399d9116295 | Q1 | LINCOLN PARK GROUP L.L.C. | 401104374 | CANADIAN INTERNATIONAL PHARMACY ASSOCIATION | 2019 | first_quarter | PHA | Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2019-04-10T15:27:48.420000-04:00 | |
| 2263614 | KATE MOSS 964c82f9-219c-40d4-9bfd-7189e3144079 | Q1 | KATE MOSS | 25988 | CVS HEALTH | 2019 | first_quarter | PHA | Legislation impacting pharmacy benefit managers. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2019-04-10T15:49:05.760000-04:00 | |
| 2263671 | SIMS STRATEGIES, LLC d7c20d7a-cd26-4f41-84b5-785f5a943470 | Q1 | SIMS STRATEGIES, LLC | 401104546 | GLAXOSMITHKLINE, INC. | 2019 | first_quarter | PHA | Education and importance of various pharmaceutical industry issues, including issues affecting vaccines and shortages. | SENATE | 40000 | 0 | 0 | 2019-04-10T16:49:33.343000-04:00 | |
| 2263733 | BROYDRICK & ASSOCIATES caa0c200-1579-4860-99ac-1f9d91497b7e | Q1 | BROYDRICK & ASSOCIATES | 7268 | EXELA PHARMA SCIENCES | 2019 | first_quarter | PHA | Drug shortages and FDA approval. USTR acceptance. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2019-04-10T21:35:22.957000-04:00 | |
| 2263748 | BROYDRICK & ASSOCIATES 3f9413c3-a77f-41d7-90a0-3d13238c89bd | Q1 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2019 | first_quarter | PHA | Funding new drug for PTSD. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-10T21:48:34.083000-04:00 | |
| 2263817 | NVG, LLC 84349501-3b69-4172-9d8e-2a24b10cf504 | Q1 | NVG, LLC | 76833 | MANATT, PHELPS AND PHILLIPS, LLP (ON BEHALF OF NEKTAR THERAPEUTICS) | 2019 | first_quarter | PHA | FDA oversight of certain pain reliever products. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-04-11T09:56:29.080000-04:00 | |
| 2263974 | 4C COMMUNICATIONS, INC. f4973b9b-3358-4b68-b7c2-8cf4e92e1173 | Q1 | 4C COMMUNICATIONS, INC. | 323717 | HEALTHCARE LEADERSHIP COUNCIL | 2019 | first_quarter | PHA | Discussion on pharmaceutical drug pricing | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-04-11T11:57:04.343000-04:00 | ||
| 2263996 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 84a0ffb0-8534-4e3a-bdf9-b641f68a4e79 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2019 | first_quarter | PHA | HR 1409, Cancer Drug Coverage Parity Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2019-04-11T12:11:13.627000-04:00 | |
| 2264007 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 9fcd6c67-988e-46d5-9ad7-283a4d857f7f | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2019 | first_quarter | PHA | Issues related to the 340B drug discount program and drug pricing policies | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-11T12:15:16.977000-04:00 | |
| 2264016 | THORSEN FRENCH ADVOCACY LLC 150c8623-2d55-4aa0-9aa0-896d5479391b | Q1 | THORSEN FRENCH ADVOCACY LLC | 400599826 | HEALTHCARE DISTRIBUTION ALLIANCE | 2019 | first_quarter | PHA | General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-11T12:17:21.120000-04:00 | |
| 2264024 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. d9c94825-b406-4525-b6e3-e47580042fa7 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2019 | first_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2019-04-11T12:21:24.703000-04:00 | |
| 2264069 | THORSEN FRENCH ADVOCACY LLC bdc5ed90-32ef-4a1b-8713-9c22bc9d8d25 | Q1 | THORSEN FRENCH ADVOCACY LLC | 400599826 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2019 | first_quarter | PHA | Issues related to pharmaceutical market value. H.R.965/S.340: CREATES Act of 2019. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-11T12:47:40.597000-04:00 | |
| 2264246 | JOHNSON MATTHEY INC. f83bf0bd-928d-4e49-927b-e05121aee3ed | Q1 | JOHNSON MATTHEY INC. | 401104441 | JOHNSON MATTHEY INC. | 2019 | first_quarter | PHA | H.R. 965 and S. 340 CREATES Act of 2019, including provisions related to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, including provisions related to discouraging parking of the 180-day exclusivity period for first generic companies challenging pharmaceutical patents. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, including provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, including provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, including provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, including provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, including provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers. | Commerce, Dept of (DOC),Environmental Protection Agency (EPA),Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-11T15:28:59.737000-04:00 | |
| 2264510 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER ed4c2a27-d660-4889-94da-cc9bed4acc76 | Q1 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2019 | first_quarter | PHA | Drug pricing, PCORI re-authorization | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 40568 | 0 | 0 | 2019-04-12T10:03:07.977000-04:00 | |
| 2264875 | 60 PLUS ASSOCIATION 9e596569-74d8-4933-9fea-a300b671bb52 | Q1 | 60 PLUS ASSOCIATION | 41988 | 60 PLUS ASSOCIATION | 2019 | first_quarter | PHA | Support affordable drug pricing, 349 B. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 0 | 0 | 2019-04-12T14:45:35.763000-04:00 | ||
| 2265033 | 340B HEALTH d07d873e-677a-445a-86f2-9c1d14b69795 | Q1 | 340B HEALTH | 316434 | 340B HEALTH | 2019 | first_quarter | PHA | The 340B Drug Pricing Program; FY 2020 L-HHS Appropriations; final rules regarding 340B ceiling price calculations and manufacturer civil monetary penalties. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 274078 | 0 | 0 | 2019-04-12T17:31:48.787000-04:00 | |
| 2265096 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 193b386d-cf04-4ac6-9717-8e2ce2884e95 | Q1 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) | 401105192 | CVS HEALTH | 2019 | first_quarter | PHA | Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. Issues related to the proposed CVS-Aetna merger. | HOUSE OF REPRESENTATIVES | 15000 | 0 | 0 | 2019-04-13T06:44:22.317000-04:00 | |
| 2265202 | FLYNN & ASSOCIATES, INC. f62b4abe-ec14-44f1-b1d8-52b07dffc287 | Q1 | FLYNN & ASSOCIATES, INC. | 15020 | PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION | 2019 | first_quarter | PHA | HR. 1344 Competitive DRUGS Act of 2019 | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-04-14T15:26:52.517000-04:00 | |
| 2265270 | CHATMAN, LLC f02bf2bf-09c4-4fb8-bcc3-07e31a7bfead | Q1 | CHATMAN, LLC | 400678024 | LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER | 2019 | first_quarter | PHA | Maintain the 340B program for hospitals | Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2019-04-14T21:54:28.257000-04:00 | |
| 2265293 | ACG ADVOCACY 67d9c312-f43e-44cd-b207-78c2bcc9d78c | Q1 | ACG ADVOCACY | 2057 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2019 | first_quarter | PHA | Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. Issues regarding direct and indirect renumeration under Medicare Part D plans. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-04-15T08:11:40.803000-04:00 | |
| 2265418 | TAUZIN STRATEGIC NETWORKS 2e205a4e-2dee-4c6a-8397-756ed17fe231 | Q1 | TAUZIN STRATEGIC NETWORKS | 400786367 | CAPTURERX | 2019 | first_quarter | PHA | Issues related to the 340b program | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-15T10:11:33.110000-04:00 | |
| 2265733 | PUBLIC CITIZEN d3d83d14-cdd9-4712-80f8-27054c0369c2 | Q1 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2019 | first_quarter | PHA | HR 1046/S 377-Medicare Negotiation and Competitive Licensing Act, Drug Pricing, HR 965-CREATES Act, Medicare for all Act, S 378/HR 1093-Stop price gouging Act, HR 985-Fast Generics act, HR 1499-Protecting consumer access to generic drugs act, HR 1506-FAIR generics act, | HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR) | 80000 | 0 | 0 | 2019-04-15T13:11:36.403000-04:00 | |
| 2265897 | NATIONAL HOME INFUSION ASSOCIATION 530d993c-ee60-4a14-a85e-d103248c07e8 | Q1 | NATIONAL HOME INFUSION ASSOCIATION | 40047365 | NATIONAL HOME INFUSION ASSOCIATION | 2019 | first_quarter | PHA | FDA MOU | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 20000 | 0 | 0 | 2019-04-15T14:24:41.513000-04:00 | |
| 2266446 | CONNECT 4 STRATEGIES, LLC 008e93cb-7be8-473c-a30f-9fd27a7fa3a2 | Q1 | CONNECT 4 STRATEGIES, LLC | 401103720 | AKCEA THERAPEUTICS, INC. | 2019 | first_quarter | PHA | FDA drug approval issues | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-15T21:03:09.257000-04:00 | |
| 2266589 | SGR LLC GOVERNMENT RELATIONS AND LOBBYING 6f6ca064-1d35-4a2a-8bf0-50837cc01093 | 1T | SGR LLC GOVERNMENT RELATIONS AND LOBBYING | 401103335 | LEVIN, PAPANTONIO, THOMAS, MITCHELL, RAFFERTY & PROCTOR, P.A. | 2019 | first_quarter | PHA | PhRMA | HOUSE OF REPRESENTATIVES | 0 | 1 | 2019-04-16T09:37:43.437000-04:00 | ||
| 2266652 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 3ea4f8b5-f36e-4747-9dfa-689711ed6b7c | Q1 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2019 | first_quarter | PHA | Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number). Mandatory recall authority of the FDA Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Commerce, Dept of (DOC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 159000 | 0 | 0 | 2019-04-16T10:09:15.353000-04:00 | |
| 2266972 | ZHF CONSULTING LLC 12686698-9a17-48ed-88c0-7b4e98b9677a | Q1 | ZHF CONSULTING LLC | 401103689 | MEDISCA, INC. | 2019 | first_quarter | PHA | Opioid crisis/alternative pain medication/including defense | HOUSE OF REPRESENTATIVES,SENATE | 22500 | 0 | 0 | 2019-04-16T11:44:35.783000-04:00 | |
| 2267174 | AMERICAN PHARMACISTS ASSOCIATION 0bf954e1-7e54-4ecb-a45c-9403fca00c7d | Q1 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2019 | first_quarter | PHA | S. 988 - Improving Transparency and Accuracy in Medicare Part D Drug Spending Act H.R. 789 - To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. H.R. 803 - This bill prohibits Medicare prescription drug plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. (A "clean claim" is a Medicare claim that is free of defects such as incomplete documentation.) H.R. 1034 - Phair Pricing Act of 2019; To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program H.R. 1035 - Prescription Drug Price Transparency Act H.R. 1959 - Preserving Patient Access to Compounded Medications Act of 2019 | HOUSE OF REPRESENTATIVES,SENATE | 34000 | 0 | 0 | 2019-04-16T12:37:39.127000-04:00 | |
| 2267320 | WINNING STRATEGIES WASHINGTON 8cdcb891-4aff-4e99-94e4-75af88561e3d | Q1 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2019 | first_quarter | PHA | Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2019-04-16T13:28:23.483000-04:00 | |
| 2267377 | ALEXANDER J. BECKLES, L.L.C. 9f6638fd-1db5-4d88-a968-5fe8fdf1c570 | Q1 | ALEXANDER J. BECKLES, L.L.C. | 40038308 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2019 | first_quarter | PHA | H.R. 6505 - Medicare Negotiation and Competitive Licensing Act of 2018; Medicare Part D | HOUSE OF REPRESENTATIVES | 5000 | 0 | 0 | 2019-04-16T13:42:37.730000-04:00 | |
| 2267882 | ICE MILLER STRATEGIES LLC 860476da-925e-4657-9946-23486015120c | Q1 | ICE MILLER STRATEGIES LLC | 316057 | LIFESCIENCE LOGISTICS, LLC | 2019 | first_quarter | PHA | Issues involving the storage and distribution of pharmaceuticals and medical items. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-04-16T16:01:26.380000-04:00 | ||
| 2267998 | KOUNTOUPES DENHAM CARR & REID, LLC 1d4214f8-8051-4aba-b6e0-5ded05feac95 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GLENMARK PHARMACEUTICALS, INC., USA | 2019 | first_quarter | PHA | General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-16T16:51:20.580000-04:00 | |
| 2268073 | MR. VINCENT A. PANVINI a04f55ea-7ec3-4a2b-945d-3672f32241c2 | Q1 | MR. VINCENT A. PANVINI | 401008845 | PHRMA | 2019 | first_quarter | PHA | Position on Price Controls; Intellectual Property Rights; Patent Protections. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-04-16T18:13:00.280000-04:00 | ||
| 2268239 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 3d7cbab0-4e1d-4f6d-b4c5-11631571ebde | Q1 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 58534 | ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 2019 | first_quarter | PHA | HR 4392- To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. | HOUSE OF REPRESENTATIVES,SENATE | 13972 | 0 | 0 | 2019-04-17T09:33:36.240000-04:00 | |
| 2268255 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 17da2406-576d-4041-8c3d-18d86e1471b1 | Q1 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2019 | first_quarter | PHA | Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-17T09:39:44.123000-04:00 | |
| 2268379 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 726e6d97-f733-40d8-93bd-3a18ea23aa1a | Q1 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | INOVIO PHARMACEUTICALS | 2019 | first_quarter | PHA | Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-17T10:26:37.173000-04:00 | |
| 2268606 | KOUNTOUPES DENHAM CARR & REID, LLC 440d3e76-260f-4c50-adb6-2b8b9b4c6375 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) | 2019 | first_quarter | PHA | Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-17T11:19:54.680000-04:00 | |
| 2268765 | FARRAGUT PARTNERS LLP fa221f00-410d-4f8e-8444-faebed514fa1 | Q1 | FARRAGUT PARTNERS LLP | 401103938 | COMMUNITY ONCOLOGY ALLIANCE | 2019 | first_quarter | PHA | Issues related to pharmacy benefit managers. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-04-17T11:39:45.743000-04:00 | |
| 2268790 | FARRAGUT PARTNERS LLP 0d5637a4-6e9f-4961-bec0-f060dc9664f5 | 1A | FARRAGUT PARTNERS LLP | 401103938 | COMMUNITY ONCOLOGY ALLIANCE | 2019 | first_quarter | PHA | Issues related to pharmacy benefit managers. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-04-17T11:42:53.327000-04:00 | |
| 2268853 | MWW GROUP c0dd207a-7588-4e82-af13-f053b609b7ac | 1T | MWW GROUP | 26318 | UNITED PHARMACY PARTNERS, INC. (UPPI) | 2019 | first_quarter | PHA | Draft legislation regarding High Enriched Uranium (HEU) | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2019-04-17T11:47:15.297000-04:00 | ||
| 2268876 | UPS (UNITED PARCEL SERVICE) c5881722-2b26-4633-9425-3157ca00b039 | Q1 | UPS (UNITED PARCEL SERVICE) | 39223 | UPS (UNITED PARCEL SERVICE) | 2019 | first_quarter | PHA | -HR 3204 -National license standards for 3PLs | Commerce, Dept of (DOC),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Aviation Administration (FAA),Government Accountability Office (GAO),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Customs & Border Protection,U.S. Trade Representative (USTR) | 2070000 | 0 | 0 | 2019-04-17T11:50:24.550000-04:00 | |
| 2269027 | KOUNTOUPES DENHAM CARR & REID, LLC 905cd0f9-1071-4c8e-85e4-8d88b8a0b7a9 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) | 2019 | first_quarter | PHA | Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. H. R. 6, SUPPORT for Patients and Communities Act. | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 60000 | 0 | 0 | 2019-04-17T12:14:16.117000-04:00 | |
| 2269127 | KOUNTOUPES DENHAM CARR & REID, LLC eb042ca3-bc39-4ce4-aef8-df2e94290023 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2019 | first_quarter | PHA | General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H.R.269, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-17T12:30:56.493000-04:00 | |
| 2269372 | BROWN & FORTUNATO, P.C. 919a31cd-7df5-45bb-aafb-e2a92205d77a | Q1 | BROWN & FORTUNATO, P.C. | 401104878 | PROMPTCARE COMPANIES, INC. | 2019 | first_quarter | PHA | Issues related to Medicare home infusion therapy benefit and other health care issues. | Centers For Medicare and Medicaid Services (CMS) | 8000 | 0 | 0 | 2019-04-17T13:32:23.767000-04:00 | |
| 2269446 | ISEMAN & ASSOCIATES LLC f8112e29-9c2b-466f-9aee-736b717cd66b | Q1 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2019 | first_quarter | PHA | Monitoring biotech legislation; prescription drug prices | HOUSE OF REPRESENTATIVES,SENATE | 12500 | 0 | 0 | 2019-04-17T13:49:00.107000-04:00 | |
| 2269525 | GOVERNMENT COUNSEL, LLC 0c98dc40-0d6a-4b51-8e9d-7c978641d641 | Q1 | GOVERNMENT COUNSEL, LLC | 401105070 | HEALTHCARE DISTRIBUTION ALLIANCE | 2019 | first_quarter | PHA | General issues related to opioid abuse (implementation of Public Law 115-271) and ARCOS data. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2019-04-17T14:03:26.980000-04:00 | |
| 2269623 | NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS c90dda68-7e87-4b8a-b40d-5161d15aab71 | Q1 | NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS | 26808 | NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS | 2019 | first_quarter | PHA | HR 938: A bill to amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes HR 1520: A bill to amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes. HR 1503: A bill to amend the Federal Food, Drug, and Cosmetic Act regarding the list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, and for other purposes. HR 1499: A bill prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes. HR 965: promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products. | Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,Treasury, Dept of,White House Office | 330000 | 0 | 0 | 2019-04-17T14:29:07.787000-04:00 | |
| 2270104 | TRAVERE THERAPEUTICS 6eb39afe-b211-459c-84c7-b195dd99c2ae | Q1 | TRAVERE THERAPEUTICS | 401104190 | TRAVERE THERAPEUTICS | 2019 | first_quarter | PHA | H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 280000 | 0 | 0 | 2019-04-17T15:52:10.077000-04:00 | |
| 2270412 | OREGON HEALTH & SCIENCE UNIVERSITY 167839ae-5a59-49f3-aa3c-3eb43a0a8b75 | Q1 | OREGON HEALTH & SCIENCE UNIVERSITY | 30291 | OREGON HEALTH & SCIENCE UNIVERSITY | 2019 | first_quarter | PHA | 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2019-04-17T16:58:56.620000-04:00 | |
| 2270473 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 9aba5f32-1b94-469c-baf0-0734b21c3e11 | Q1 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2019 | first_quarter | PHA | Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844) Implementation of Public Law 113-54 (DSCSA) | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 301047 | 0 | 0 | 2019-04-17T17:28:19.770000-04:00 | |
| 2270904 | MEHLMAN CONSULTING, INC. 49d3d88c-9c88-42e2-bde8-df901775e3ea | Q1 | MEHLMAN CONSULTING, INC. | 284950 | BLUE SHIELD OF CALIFORNIA | 2019 | first_quarter | PHA | Prescription drug pricing. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2019-04-18T09:04:09.033000-04:00 | |
| 2270973 | WAXMAN STRATEGIES a0bc050d-b214-4353-9363-fc9419b50869 | Q1 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2019 | first_quarter | PHA | Issues affecting the 340B drug pricing program; Appropriations for 340B program. | HOUSE OF REPRESENTATIVES | 60000 | 0 | 0 | 2019-04-18T09:11:27.947000-04:00 | |
| 2271191 | FAEGRE BAKER DANIELS CONSULTING da5a4914-5b6a-4126-b0a1-fdc3558257cc | Q1 | FAEGRE BAKER DANIELS CONSULTING | 34158 | ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP) | 2019 | first_quarter | PHA | Illicit prescription drug sales online; rouge internet drug sellers; danger of counterfeit medicines | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 70000 | 0 | 0 | 2019-04-18T09:33:28.340000-04:00 | |
| 2271225 | FAEGRE BAKER DANIELS CONSULTING 9ae8aefa-327e-4ad9-8a44-ab60c6ccbf56 | Q1 | FAEGRE BAKER DANIELS CONSULTING | 34158 | NATIONAL ASSOCIATION OF BOARDS OF PHARMACY | 2019 | first_quarter | PHA | Pharmacy regulation; Prescription drug monitoring | Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE | 110000 | 0 | 0 | 2019-04-18T09:37:38.423000-04:00 | |
| 2271335 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 73a96ff6-f180-46c6-a9c3-cbaab15c5868 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2019 | first_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2019-04-18T10:05:26.900000-04:00 | |
| 2271403 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES f69c47f1-906b-474a-8a0e-fa2e80aabe12 | Q1 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 26672 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2019 | first_quarter | PHA | H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act | HOUSE OF REPRESENTATIVES,SENATE | 1080000 | 0 | 0 | 2019-04-18T10:18:51.083000-04:00 | |
| 2271648 | COVINGTON & BURLING LLP 638f11ac-8fb0-4ce7-9bf1-024681966436 | Q1 | COVINGTON & BURLING LLP | 11195 | CELGENE CORPORATION | 2019 | first_quarter | PHA | Expressing support for changes to the CREATES Act (S. 340) and Fair Access for Safe and timely (FAST) Generics Act (H.R. 985) | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2019-04-18T10:51:18.067000-04:00 | |
| 2271747 | BLUE CROSS AND BLUE SHIELD ASSOCIATION 41114586-d635-4296-8862-557a4ba9c10e | Q1 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 6358 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2019 | first_quarter | PHA | Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act;Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars H.R.1781 - 116th Congress (2019-2020) Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R.938 - 116th Congress (2019-2020) BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 - 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office | 1580000 | 0 | 0 | 2019-04-18T11:07:00.487000-04:00 | |
| 2271902 | AMERICAN CONSERVATIVE UNION fcca2bf5-d03a-4dd0-8cd8-915e8dd5c849 | Q1 | AMERICAN CONSERVATIVE UNION | 62712 | AMERICAN CONSERVATIVE UNION | 2019 | first_quarter | PHA | Administrative rule making on efforts on amending the safe harbor regulation concerning discounts, of prescription pharmaceutical products in Medicare/Medicaid. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,White House Office | 10000 | 0 | 0 | 2019-04-18T11:27:57.317000-04:00 | |
| 2271992 | BALLARD PARTNERS ba37b4bb-686f-4a7e-bf0d-d1efec468164 | Q1 | BALLARD PARTNERS | 401104288 | LABORATORY CORPORATIONS OF AMERICA HOLDINGS | 2019 | first_quarter | PHA | Clinical Lab Rates | Health & Human Services, Dept of (HHS),White House Office | 80000 | 0 | 0 | 2019-04-18T11:37:36.183000-04:00 | |
| 2272178 | FTI GOVERNMENT AFFAIRS 434d1915-4852-4073-8a74-c4e566e7aa54 | Q1 | FTI GOVERNMENT AFFAIRS | 401054971 | PERRIGO, INC. | 2019 | first_quarter | PHA | Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", H.R. 5333. "Over-the-Counter Drug Safety, Innovation, and Reform Act", S. 2315. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2019-04-18T12:04:44.317000-04:00 | |
| 2272544 | ACADEMY OF MANAGED CARE PHARMACY 33a30158-f00c-4a08-b0f2-94561db1fe2b | Q1 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2019 | first_quarter | PHA | Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date) | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2019-04-18T13:05:57.263000-04:00 | |
| 2272671 | HANCE SCARBOROUGH 051fca8e-11a1-46df-801c-4e52908c2aab | Q1 | HANCE SCARBOROUGH | 17443 | TITAN PHARMACEUTICALS, INC. | 2019 | first_quarter | PHA | Medicare/Medicaid drug coverage, opioid addiction policy. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2019-04-18T13:21:36.653000-04:00 | ||
| 2272797 | HANCE SCARBOROUGH b42e2dcd-6574-457c-936b-f61e6564f167 | Q1 | HANCE SCARBOROUGH | 17443 | ALLIANCE FOR PHARMACY COMPOUNDING | 2019 | first_quarter | PHA | Issues related to the regulation of pharmacy compounding. HR 1959 Preserving Patient Access to Compounded Medications Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2019-04-18T13:36:18.773000-04:00 | |
| 2273161 | ELI LILLY AND COMPANY e617af2e-9bde-4f81-98ec-ed75ad64c6af | Q1 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2019 | first_quarter | PHA | Hospital discounts; 340B program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1370000 | 0 | 0 | 2019-04-18T14:40:41.617000-04:00 | |
| 2273375 | AARP 9c3769ff-873c-4a30-bd56-95e1f42202f9 | Q1 | AARP | 1694 | AARP | 2019 | first_quarter | PHA | H.R. 21, Consolidated Appropriations Act FY 2019, H.R. 648, 2nd Consolidated Appropriations Act FY 2019, H.J.R. 31 Continuing Appropriations for Homeland Security FY 2019, H.J.R. 143, H.R. 695, Short-term Continuing Appropriations Act Resolution FY 2019, Agriculture-Rural Development Appropriations bill (no bill numbers) - lobbied to protect funding for FDA drug processing funding and user fees. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,Transportation, Dept of (DOT) | 1840000 | 0 | 0 | 2019-04-18T15:11:03.613000-04:00 | |
| 2273410 | KOUNTOUPES DENHAM CARR & REID, LLC ef5e96dd-235b-4370-beb9-b5448ee52ea8 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2019 | first_quarter | PHA | General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2019-04-18T15:17:12.010000-04:00 | |
| 2273486 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31fda5d5-1fed-4da1-b0da-c2332741ddce | Q1 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 31348 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2019 | first_quarter | PHA | Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE | 1492460 | 0 | 0 | 2019-04-18T15:30:44.147000-04:00 | |
| 2273591 | ROCK & ASSOCIATES 35b94649-c95c-487c-8ec8-13d375f2176b | Q1 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2019 | first_quarter | PHA | H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2019-04-18T15:47:28.147000-04:00 | |
| 2273609 | THE LIVINGSTON GROUP, LLC 17a30b10-7d87-4466-aa6e-7f4ce8d74e65 | Q1 | THE LIVINGSTON GROUP, LLC | 49635 | RUSH UNIVERSITY MEDICAL CENTER | 2019 | first_quarter | PHA | Maintain the 340B program for hospitals | Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2019-04-18T15:48:31.567000-04:00 | |
| 2273679 | ROCK & ASSOCIATES 104ecded-3658-49ea-9bf5-7f6e5a8de2dd | Q1 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2019 | first_quarter | PHA | H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2019-04-18T15:51:44.307000-04:00 | |
| 2273697 | ROCK & ASSOCIATES 7a5f3daf-b46d-421c-baba-7d8a6e9f75c1 | Q1 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2019 | first_quarter | PHA | H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2019-04-18T15:54:51.150000-04:00 | |
| 2273704 | ROCK & ASSOCIATES 2b3d4e94-c746-41f2-aff4-019be19c8c60 | Q1 | ROCK & ASSOCIATES | 33545 | WELLNESS PHARMACY | 2019 | first_quarter | PHA | H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2019-04-18T15:55:54.950000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);